Eliminating viral hepatitis C in Belgium: the micro-elimination approach

被引:11
作者
Busschots, Dana [1 ,2 ]
Toghanian, Samira [3 ]
Bielen, Rob [1 ,2 ]
Salomonsson, Stina [3 ]
Koc, Ozguer M. [1 ,2 ,4 ]
Hendrickx, Greet [5 ]
Jadoul, Michel [6 ]
Nevens, Frederik [7 ]
Sokal, Etienne [8 ]
Brixko, Christian [9 ]
Peerlinck, Kathelijne [10 ]
Apers, Ludwig [11 ]
Robaeys, Geert [1 ,2 ,7 ]
Lazarus, Jeffrey V. [12 ]
机构
[1] Hasselt Univ, Fac Hlth & Life Sci, Diepenbeek, Belgium
[2] Ziekenhuis Oost Limburg, Dept Gastroenterol & Hepatol, Genk, Belgium
[3] Ctr Observat Real world Evidence CORE, MSD, Stockholm, Sweden
[4] Maastricht Univ Med Ctr, Sch NUTRIM, Med Microbiol, Maastricht, Netherlands
[5] Univ Antwerp, Vaccine & Infect Dis Inst, Ctr Evaluat Vaccinat, Viral Hepatitis Prevent Board, Antwerp, Belgium
[6] Catholic Univ Louvain, Clin Univ St Luc, Serv Nephrol, Brussels, Belgium
[7] Univ Hosp KU Leuven, Dept Gastroenterol & Hepatol, Leuven, Belgium
[8] Catholic Univ Louvain, Clin Univ St Luc, Serv Gastroenterol Hepatol Pediatr, Brussels, Belgium
[9] CHR Citadelle, Dept Hepatogastroenterol & Digest Oncol, Liege, Belgium
[10] Univ Hosp KU Leuven, Haemophilia Ctr, Div Cardiovasc Disorders, Leuven, Belgium
[11] Inst Trop Med Antwerp, Dept Clin Sci, Antwerp, Belgium
[12] Univ Barcelona, Barcelona Inst Global Hlth ISGlobal, Hosp Clin, Barcelona, Spain
关键词
Disease elimination; Health policy; Hepatitis C; Treatment; Belgium; SOFOSBUVIR PLUS RIBAVIRIN; VIRUS HCV INFECTION; HIV-POSITIVE MSM; LIVER-DISEASE; INJECT DRUGS; PREEXPOSURE PROPHYLAXIS; TRANSMISSION; PEOPLE; BURDEN; HEMODIALYSIS;
D O I
10.1186/s12879-020-4898-y
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
BackgroundHepatitis C virus is one of the leading causes of chronic liver disease and liver-related deaths worldwide. The estimated prevalence of chronic hepatitis C viral infection among the general Belgian population was 0.57% (n=64,000) in 2015. Although Belgium has had a 'Hepatitis C Plan' since 2014, elimination efforts are unclear. This study employs the best available data and modelling estimates to define the burden of hepatitis C viral infection among key subgroups in Belgium, identify information gaps and propose potential approaches to screening, linkage to care and treatment, and cure.MethodsWe examined the peer-reviewed and grey literature since 2012 for data on the prevalence of hepatitis C viral infection in Belgium in key subgroups identified by national experts and in the literature. Ultimately, this research is primarily based on data provided by the key stakeholders themselves due to a lack of reliable data in the literature. Based on this, we modelled the treatment rates required to reach elimination of hepatitis C in several subgroups.ResultsEleven potential subgroups were identified. There were no data available for two subgroups: generational cohorts and men who have sex with men. In six subgroups, fewer than 3000 people were reported or estimated to have hepatitis C infection. Migrants and people who inject drugs were the most affected subgroups, and children were the least affected subgroup. Only two subgroups are on target to achieve elimination by 2030: patients living with haemophilia and transplant recipients.ConclusionsRemoving Belgian treatment reimbursement restrictions in January 2019 was a big step towards eliminating HCV. In addition, increasing surveillance, including with a national registry, treatment prescription by other health-care providers and availability of treatment in local pharmacies are central to improving the current situation and getting on track to reach the 2030 WHO hepatitis C elimination targets in Belgium.
引用
收藏
页数:12
相关论文
共 94 条
  • [61] Geographic Differences in Temporal Incidence Trends of Hepatitis C Virus Infection Among People Who Inject Drugs: The InC3 Collaboration
    Morris, Meghan D.
    Shiboski, Stephen
    Bruneau, Julie
    Hahn, Judith A.
    Hellard, Margaret
    Prins, Maria
    Cox, Andrea L.
    Dore, Gregory
    Grebely, Jason
    Kim, Arthur Y.
    Lauer, Georg M.
    Lloyd, Andrew
    Rice, Thomas
    Shoukry, Naglaa
    Maher, Lisa
    Page, Kimberly
    [J]. CLINICAL INFECTIOUS DISEASES, 2017, 64 (07) : 860 - 869
  • [62] Mulkay JP, 2017, 2017 VIR HEP PREV BO
  • [63] Muyldermans G, 2016, JAARRAPPORT 2016 HEP
  • [64] Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013
    Naghavi, Mohsen
    Wang, Haidong
    Lozano, Rafael
    Davis, Adrian
    Liang, Xiaofeng
    Zhou, Maigeng
    Vollset, Stein Emil
    Ozgoren, Ayse Abbasoglu
    Abdalla, Safa
    Abd-Allah, Foad
    Aziz, Muna I. Abdel
    Abera, Semaw Ferede
    Aboyans, Victor
    Abraham, Biju
    Abraham, Jerry P.
    Abuabara, Katrina E.
    Abubakar, Ibrahim
    Abu-Raddad, Laith J.
    Abu-Rmeileh, Niveen M. E.
    Achoki, Tom
    Adelekan, Ademola
    Ademi, Zanfina
    Adofo, Koranteng
    Adou, Arsene Kouablan
    Adsuar, Jose C.
    Arnlov, Johan
    Agardh, Emilie Elisabet
    Akena, Dickens
    Al Khabouri, Mazin J.
    Alasfoor, Deena
    Albittar, Mohammed
    Alegretti, Miguel Angel
    Aleman, Alicia V.
    Alemu, Zewdie Aderaw
    Alfonso-Cristancho, Rafael
    Alhabib, Samia
    Ali, Mohammed K.
    Ali, Raghib
    Alla, Francois
    Al Lami, Faris
    Allebeck, Peter
    AlMazroa, Mohammad A.
    Salman, Rustam Al-Shahi
    Alsharif, Ubai
    Alvarez, Elena
    Alviz-Guzman, Nelson
    Amankwaa, Adansi A.
    Amare, Azmeraw T.
    Ameli, Omid
    Amini, Hassan
    [J]. LANCET, 2015, 385 (9963) : 117 - 171
  • [65] What's new in hepatitis C virus infections in children?
    Pawlowska, Malgorzata
    Domagalski, Krzysztof
    Pniewska, Anna
    Smok, Beata
    Halota, Waldemar
    Tretyn, Andrzej
    [J]. WORLD JOURNAL OF GASTROENTEROLOGY, 2015, 21 (38) : 10783 - 10789
  • [66] Needle and syringe programmes and opioid substitution therapy for preventing HCV transmission among people who inject drugs: findings from a Cochrane Review and meta-analysis
    Platt, Lucy
    Minozzi, Silvia
    Reed, Jennifer
    Vickerman, Peter
    Hagan, Holly
    French, Clare
    Jordan, Ashly
    Degenhardt, Louisa
    Hope, Vivian
    Hutchinson, Sharon
    Maher, Lisa
    Palmateer, Norah
    Taylor, Avril
    Bruneau, Julie
    Hickman, Matthew
    [J]. ADDICTION, 2018, 113 (03) : 545 - 563
  • [67] Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis
    Platt, Lucy
    Easterbrook, Philippa
    Gower, Erin
    McDonald, Bethan
    Sabin, Keith
    McGowan, Catherine
    Yanny, Irini
    Razavi, Homie
    Vickerman, Peter
    [J]. LANCET INFECTIOUS DISEASES, 2016, 16 (07) : 797 - 808
  • [68] The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm
    Razavi, H.
    Waked, I.
    Sarrazin, C.
    Myers, R. P.
    Idilman, R.
    Calinas, F.
    Vogel, W.
    Mendes Correa, M. C.
    Hezode, C.
    Lazaro, P.
    Akarca, U.
    Aleman, S.
    Balik, I.
    Berg, T.
    Bihl, F.
    Bilodeau, M.
    Blasco, A. J.
    Brandao Mello, C. E.
    Bruggmann, P.
    Buti, M.
    Calleja, J. L.
    Cheinquer, H.
    Christensen, P. B.
    Clausen, M.
    Coelho, H. S. M.
    Cramp, M. E.
    Dore, G. J.
    Doss, W.
    Duberg, A. S.
    El-Sayed, M. H.
    Ergor, G.
    Esmat, G.
    Falconer, K.
    Felix, J.
    Ferraz, M. L. G.
    Ferreira, P. R.
    Frankova, S.
    Garcia-Samaniego, J.
    Gerstoft, J.
    Giria, J. A.
    Goncales, F. L., Jr.
    Gower, E.
    Gschwantler, M.
    Guimaraes Pessoa, M.
    Hindman, S. J.
    Hofer, H.
    Husa, P.
    Kaberg, M.
    Kaita, K. D. E.
    Kautz, A.
    [J]. JOURNAL OF VIRAL HEPATITIS, 2014, 21 : 34 - 59
  • [69] The Cost-Effectiveness of Birth-Cohort Screening for Hepatitis C Antibody in US Primary Care Settings
    Rein, David B.
    Smith, Bryce D.
    Wittenborn, John S.
    Lesesne, Sarah B.
    Wagner, Laura D.
    Roblin, Douglas W.
    Patel, Nita
    Ward, John W.
    Weinbaum, Cindy M.
    [J]. ANNALS OF INTERNAL MEDICINE, 2012, 156 (04) : 263 - U24
  • [70] Sexual transmission of hepatitis c in MSM may not be confined to those with HIV infection
    Richardson, Daniel
    Fisher, Martin
    Sabin, Caroline A.
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2008, 197 (08) : 1213 - 1214